

## Quarterly update & Appendix 4C webinar 11:00am AEST Thursday 31 July

**Sydney, Australia, 29 July 2025** – PainChek Ltd (ASX: PCK) ("PainChek" or "the Company"), developer of the world's first smart device-based pain assessment and monitoring application, is pleased to announce that it will hold an investor webinar following the announcement of the Company's quarterly update and Appendix 4C.

The quarterly update is expected to be lodged pre-market open on 31<sup>st</sup> July 2025.

CEO Philip Daffas will then deliver the latest investor presentation as part of a webinar, to be held at 11:00am AEST Thursday 31 July 2025.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: <u>https://us02web.zoom.us/webinar/register/WN\_bH488ZNUTOiUg\_A5sBlCpQ</u>

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted on the day or sent in advance to <u>benl@nwrcommunications.com.au</u>.

Please note a replay of the webinar will be available at the above-mentioned link shortly following the conclusion of the live session.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo Company Secretary, PainChek <u>natalie.climo@boardroomlimited.com.au</u> 02 8016 2875 Philip Daffas CEO, PainChek philip.daffas@painchek.com 0406 537 235

## About PainChek

<u>PainChek</u><sup>\*</sup> is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek<sup>®</sup> app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek<sup>®</sup> Analytics.

**ABN** 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000

E: info@painchek.com W: painchek.com

PainChek Limited (ASX: PCK) | PG 1

Globally, PainChek<sup>®</sup> has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek<sup>®</sup> has contracts with over 1,900 aged care facilities, with more than 12,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek<sup>®</sup>, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek<sup>®</sup> tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peerreviewed journals including the <u>Journal of Alzheimer's Disease</u>. An article in <u>BMC Geriatrics</u> indicates that PainChek<sup>®</sup> is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found <u>here.</u>

PainChek<sup>\*</sup>has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated <u>PainChek<sup>\*</sup> Infant app</u> identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: https://painchek.com

**ABN** 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000

E: info@painchek.com W: painchek.com

PainChek Limited (ASX: PCK) | PG 2